Group Completes First Dose of Stem Cells for Bradykinesia

Group Completes First Dose of Stem Cells for Bradykinesia

288527

Group Completes First Dose of Stem Cells for Bradykinesia

IMAC Holdings has completed dosing the first group of participants in a Phase 1 clinical trial evaluating its investigational umbilical cord-derived mesenchymal stem cells (MSCs) as a potential treatment for bradykinesia, a common motor symptom of Parkinson’s disease. The group consists of five patients who received a low dose of the stem cell treatment by Feb. 26, IMAC Holdings, the therapy’s developer, announced in a press release. Researchers will wait 30 days to demonstrate the…

You must be logged in to read/download the full post.